{"product_id":"mskcc-foundations-in-immunotherapy-in-the-oncology-population-2026","title":"MSKCC Foundations in Immunotherapy in the Oncology Population 2026","description":"\u003ch1 data-section-id=\"achm0m\" data-start=\"0\" data-end=\"67\"\u003eMSKCC Foundations in Immunotherapy in the Oncology Population 2026\u003c\/h1\u003e\r\n\u003ch2 data-section-id=\"11plxg4\" data-start=\"68\" data-end=\"107\"\u003eComprehensive Immuno-Oncology Course\u003c\/h2\u003e\r\n\r\n\u003chr data-start=\"109\" data-end=\"112\"\u003e\r\n\r\n\u003ch2 data-section-id=\"l63aon\" data-start=\"114\" data-end=\"128\"\u003e📌 Overview\u003c\/h2\u003e\r\n\u003cp data-start=\"130\" data-end=\"351\"\u003eThe \u003cstrong data-start=\"134\" data-end=\"237\"\u003eMemorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026\u003c\/strong\u003e is a high-impact, evidence-based course focused on \u003cstrong data-start=\"289\" data-end=\"350\"\u003emodern cancer immunotherapy and its clinical applications\u003c\/strong\u003e.\u003c\/p\u003e\r\n\u003cp data-start=\"353\" data-end=\"663\"\u003eDelivered by experts from \u003cspan class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"\u003e\u003cspan class=\"whitespace-normal\"\u003eMemorial Sloan Kettering Cancer Center\u003c\/span\u003e\u003c\/span\u003e, this program provides a \u003cstrong data-start=\"442\" data-end=\"541\"\u003edeep dive into checkpoint inhibitors, CAR T-cell therapy, and emerging immunotherapy strategies\u003c\/strong\u003e, with a strong emphasis on \u003cstrong data-start=\"569\" data-end=\"624\"\u003ereal-world toxicity management and patient outcomes\u003c\/strong\u003e .\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"665\" data-end=\"668\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1dztrgh\" data-start=\"670\" data-end=\"690\"\u003e📦 Course Details\u003c\/h2\u003e\r\n\u003cul data-start=\"692\" data-end=\"865\"\u003e\r\n \t\u003cli data-section-id=\"mdm51k\" data-start=\"692\" data-end=\"727\"\u003e🎥 \u003cstrong data-start=\"697\" data-end=\"725\"\u003e23 Video Lectures (.mp4)\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lamzbb\" data-start=\"728\" data-end=\"758\"\u003e📝 \u003cstrong data-start=\"733\" data-end=\"756\"\u003e23 Subtitles (.vtt)\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ng5rid\" data-start=\"759\" data-end=\"783\"\u003e📄 \u003cstrong data-start=\"764\" data-end=\"781\"\u003e20 PDF Slides\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mz24uf\" data-start=\"784\" data-end=\"814\"\u003e💾 \u003cstrong data-start=\"789\" data-end=\"812\"\u003eTotal Size: 4.97 GB\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ts66hh\" data-start=\"815\" data-end=\"865\"\u003e📅 Date: January 28, 2026 (Online CME Program)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"867\" data-end=\"870\"\u003e\r\n\r\n\u003ch2 data-section-id=\"myexar\" data-start=\"872\" data-end=\"893\"\u003e🎯 Target Audience\u003c\/h2\u003e\r\n\u003cul data-start=\"895\" data-end=\"1064\"\u003e\r\n \t\u003cli data-section-id=\"1fxqai6\" data-start=\"895\" data-end=\"946\"\u003eOncologists (medical, hematologic, solid tumor)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"4z3lre\" data-start=\"947\" data-end=\"976\"\u003eImmunotherapy specialists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"110ievh\" data-start=\"977\" data-end=\"1023\"\u003eNurse practitioners \u0026amp; physician assistants\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e0itfl\" data-start=\"1024\" data-end=\"1064\"\u003eHospitalists and oncology care teams\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1066\" data-end=\"1069\"\u003e\r\n\r\n\u003ch2 data-section-id=\"rzhzfj\" data-start=\"1071\" data-end=\"1094\"\u003e🧠 What You’ll Learn\u003c\/h2\u003e\r\n\r\n\u003chr data-start=\"1096\" data-end=\"1099\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1vsztbo\" data-start=\"1101\" data-end=\"1137\"\u003e🧬 Core Immunotherapy Principles\u003c\/h3\u003e\r\n\u003cul data-start=\"1138\" data-end=\"1276\"\u003e\r\n \t\u003cli data-section-id=\"zsqq7d\" data-start=\"1138\" data-end=\"1189\"\u003eImmune system fundamentals (innate vs adaptive)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"rc2fz7\" data-start=\"1190\" data-end=\"1239\"\u003eMechanisms of action of checkpoint inhibitors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"rk0olk\" data-start=\"1240\" data-end=\"1276\"\u003eKey targets: PD-1, PD-L1, CTLA-4\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1278\" data-end=\"1281\"\u003e\r\n\r\n\u003ch3 data-section-id=\"48zf30\" data-start=\"1283\" data-end=\"1323\"\u003e🎯 Advanced Immunotherapy Modalities\u003c\/h3\u003e\r\n\u003cul data-start=\"1324\" data-end=\"1467\"\u003e\r\n \t\u003cli data-section-id=\"1gcjogl\" data-start=\"1324\" data-end=\"1365\"\u003e\u003cspan class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"\u003e\u003cspan class=\"whitespace-normal\"\u003eCAR T-cell therapy\u003c\/span\u003e\u003c\/span\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1dflhxr\" data-start=\"1366\" data-end=\"1399\"\u003eBispecific antibodies (BiTEs)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1x5cplj\" data-start=\"1400\" data-end=\"1441\"\u003eTumor-infiltrating lymphocytes (TILs)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13p1anv\" data-start=\"1442\" data-end=\"1467\"\u003eNovel immune agonists\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1469\" data-end=\"1472\"\u003e\r\n\r\n\u003ch3 data-section-id=\"fcoe9s\" data-start=\"1474\" data-end=\"1517\"\u003e🧪 Clinical Applications Across Cancers\u003c\/h3\u003e\r\n\u003cul data-start=\"1518\" data-end=\"1665\"\u003e\r\n \t\u003cli data-section-id=\"1916xwp\" data-start=\"1518\" data-end=\"1568\"\u003eSolid tumors (lung, breast, bladder, melanoma)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1puwrz8\" data-start=\"1569\" data-end=\"1627\"\u003eHematologic malignancies (leukemia, lymphoma, myeloma)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"cp4dgb\" data-start=\"1628\" data-end=\"1665\"\u003ePersonalized treatment strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1667\" data-end=\"1670\"\u003e\r\n\r\n\u003ch3 data-section-id=\"16n951r\" data-start=\"1672\" data-end=\"1714\"\u003e⚠️ Toxicity \u0026amp; Adverse Event Management\u003c\/h3\u003e\r\n\u003cul data-start=\"1715\" data-end=\"1860\"\u003e\r\n \t\u003cli data-section-id=\"kct2gt\" data-start=\"1715\" data-end=\"1756\"\u003eImmune-related adverse events (irAEs)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kqugyn\" data-start=\"1757\" data-end=\"1792\"\u003eCytokine release syndrome (CRS)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h6kr8x\" data-start=\"1793\" data-end=\"1818\"\u003eNeurotoxicity (ICANS)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12eq6b1\" data-start=\"1819\" data-end=\"1860\"\u003eDermatologic and pulmonary toxicities\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1862\" data-end=\"1865\"\u003e\r\n\r\n\u003ch3 data-section-id=\"xhs77x\" data-start=\"1867\" data-end=\"1905\"\u003e🧠 Precision Oncology \u0026amp; Biomarkers\u003c\/h3\u003e\r\n\u003cul data-start=\"1906\" data-end=\"2021\"\u003e\r\n \t\u003cli data-section-id=\"picrr3\" data-start=\"1906\" data-end=\"1941\"\u003ecfDNA and predictive biomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e6cqnf\" data-start=\"1942\" data-end=\"1987\"\u003ePatient selection and risk stratification\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vxtryb\" data-start=\"1988\" data-end=\"2021\"\u003eTreatment response monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"2023\" data-end=\"2026\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1t58b75\" data-start=\"2028\" data-end=\"2055\"\u003e🔬 Emerging Innovations\u003c\/h3\u003e\r\n\u003cul data-start=\"2056\" data-end=\"2183\"\u003e\r\n \t\u003cli data-section-id=\"1km0t4i\" data-start=\"2056\" data-end=\"2096\"\u003eCombination immunotherapy strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"18e6xix\" data-start=\"2097\" data-end=\"2138\"\u003eNext-generation checkpoint inhibitors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"d17yb0\" data-start=\"2139\" data-end=\"2183\"\u003eExpanding indications across tumor types\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"2185\" data-end=\"2188\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1n76lnm\" data-start=\"2190\" data-end=\"2215\"\u003e🎓 Learning Objectives\u003c\/h2\u003e\r\n\u003cp data-start=\"2217\" data-end=\"2273\"\u003eBy completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2275\" data-end=\"2572\"\u003e\r\n \t\u003cli data-section-id=\"eo1ptc\" data-start=\"2275\" data-end=\"2333\"\u003eUnderstand \u003cstrong data-start=\"2288\" data-end=\"2331\"\u003ecore mechanisms of cancer immunotherapy\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"38rqef\" data-start=\"2334\" data-end=\"2393\"\u003eApply \u003cstrong data-start=\"2342\" data-end=\"2391\"\u003eimmunotherapy strategies in clinical oncology\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17pq1rs\" data-start=\"2394\" data-end=\"2456\"\u003eDifferentiate between \u003cstrong data-start=\"2418\" data-end=\"2454\"\u003evarious immunotherapeutic agents\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"d42yso\" data-start=\"2457\" data-end=\"2512\"\u003eManage \u003cstrong data-start=\"2466\" data-end=\"2510\"\u003etoxicities and complications effectively\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"bgkw4f\" data-start=\"2513\" data-end=\"2572\"\u003eIntegrate \u003cstrong data-start=\"2525\" data-end=\"2570\"\u003eCAR T-cell therapy into clinical practice\u003c\/strong\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"2574\" data-end=\"2577\"\u003e\r\n\r\n\u003ch2 data-section-id=\"zgqs67\" data-start=\"2579\" data-end=\"2604\"\u003e📚 Key Topics Included\u003c\/h2\u003e\r\n\u003cul data-start=\"2606\" data-end=\"3062\"\u003e\r\n \t\u003cli data-section-id=\"qp3t6f\" data-start=\"2606\" data-end=\"2666\"\u003eMechanism of checkpoint blockade (PD-1 \/ PD-L1 \/ CTLA-4)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1fughu9\" data-start=\"2667\" data-end=\"2713\"\u003eCAR T-cell therapy and toxicity management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"19xzy4x\" data-start=\"2714\" data-end=\"2771\"\u003eImmunotherapy in leukemia, lymphoma, and solid tumors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"wj86q\" data-start=\"2772\" data-end=\"2824\"\u003ePneumonitis and dermatologic toxicity management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"o2jwlj\" data-start=\"2825\" data-end=\"2863\"\u003eSmall cell lung cancer innovations\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qcj1z4\" data-start=\"2864\" data-end=\"2912\"\u003eBladder, breast, and GI cancer immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gwzwum\" data-start=\"2913\" data-end=\"2958\"\u003eBispecific antibodies in multiple myeloma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17yy0v4\" data-start=\"2959\" data-end=\"3000\"\u003eSynovial sarcoma and T-cell therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qon6ra\" data-start=\"3001\" data-end=\"3031\"\u003eCRS, ICANS, and cytopenias\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n7k3j9\" data-start=\"3032\" data-end=\"3062\"\u003eCase-based Q\u0026amp;A discussions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"3064\" data-end=\"3067\"\u003e\r\n\r\n\u003ch2 data-section-id=\"fcjyt5\" data-start=\"3069\" data-end=\"3100\"\u003e⭐ Why This Course Stands Out\u003c\/h2\u003e\r\n\u003cul data-start=\"3102\" data-end=\"3374\"\u003e\r\n \t\u003cli data-section-id=\"dhhiwx\" data-start=\"3102\" data-end=\"3153\"\u003e✔️ From \u003cstrong data-start=\"3112\" data-end=\"3151\"\u003eworld-leading cancer center (MSKCC)\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"14q1cf2\" data-start=\"3154\" data-end=\"3214\"\u003e✔️ Covers \u003cstrong data-start=\"3166\" data-end=\"3212\"\u003eboth fundamentals + cutting-edge therapies\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fufd9i\" data-start=\"3215\" data-end=\"3275\"\u003e✔️ Strong focus on \u003cstrong data-start=\"3236\" data-end=\"3273\"\u003ereal clinical toxicity management\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1dotaff\" data-start=\"3276\" data-end=\"3326\"\u003e✔️ Case-based learning with practical insights\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ejd6y1\" data-start=\"3327\" data-end=\"3374\"\u003e✔️ Relevant for \u003cstrong data-start=\"3345\" data-end=\"3372\"\u003edaily oncology practice\u003c\/strong\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"3376\" data-end=\"3379\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1sb8kkc\" data-start=\"3381\" data-end=\"3401\"\u003e🚀 Clinical Value\u003c\/h2\u003e\r\n\u003cp data-start=\"3403\" data-end=\"3455\"\u003eThis course is essential for clinicians who want to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3457\" data-end=\"3700\"\u003e\r\n \t\u003cli data-section-id=\"18b8krk\" data-start=\"3457\" data-end=\"3523\"\u003eStay updated with \u003cstrong data-start=\"3477\" data-end=\"3521\"\u003erapidly evolving immunotherapy landscape\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"r6a0hj\" data-start=\"3524\" data-end=\"3580\"\u003eImprove \u003cstrong data-start=\"3534\" data-end=\"3578\"\u003epatient selection and treatment outcomes\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"4w0seb\" data-start=\"3581\" data-end=\"3644\"\u003eReduce complications through \u003cstrong data-start=\"3612\" data-end=\"3642\"\u003eearly toxicity recognition\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"cf4qna\" data-start=\"3645\" data-end=\"3700\"\u003eApply \u003cstrong data-start=\"3653\" data-end=\"3686\"\u003eprecision oncology approaches\u003c\/strong\u003e in practice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eAdvancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eAdvancing Leukemia Care Through Immuno-Oncology\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eApproaches to Immunotherapy-related Pneumonitis Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eBreast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eCheckpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eClinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eDostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003eEvolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003eIL-2-Stimulating Agents from Early Drug Development\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003eInnovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003eIntrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003eMechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003eMelanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003eNeurotoxicity in CAR T-Cell Therapy- Recognition and Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003eOverview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003eQ\u0026amp;A and Discussion – 01\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003eQ\u0026amp;A and Discussion – 02\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003eQ\u0026amp;A and Discussion – 03\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003eQ\u0026amp;A and Discussion – 04\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003eQ\u0026amp;A and Discussion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003eTargeting Multiple Myeloma with Bispecific Immune-Modulating Agents\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003eThe Role of T-Cell Therapy in Standard Care for Synovial Sarcoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003eUnderstanding Chimeric Antigen Receptor (CAR) T-Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":42954711138402,"sku":"MED-AMB08630","price":35.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/MSKCC-Foundations-in-Immunotherapy-in-the-Oncology-Population-2026_35321a0a-6931-4a03-aa84-e91c9a36b147.webp?v=1779382918","url":"https:\/\/meducourse.com\/products\/mskcc-foundations-in-immunotherapy-in-the-oncology-population-2026","provider":"Meducourse","version":"1.0","type":"link"}